Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review

Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review

Immune checkpoint inhibitors (ICIs) have become the standard of care for several types of cancer due to their superiority in terms of survival benefits in first- and second-line treatments compared to conventional therapies, and they present a better safety profile (lower absolute number of grade 1–...

Full description

Bibliographic Details
Main Authors: Marion Allouchery, Clément Beuvon, Marie-Christine Pérault-Pochat, Pascal Roblot, Mathieu Puyade, Mickaël Martin
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
safety
immune-related adverse events
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/14/4/955

Similar Items

Similar Items